提醒:代购产品,无质量问题不接受退换货,下单前请仔细核对信息。下单后请及时联系客服 核对商品价格,订单生效后再付款。
Hycult Biotech/C3b/iC3b, Human, mAb 3E7, functional study antibody, low endotoxin/HM2286-FS/0.5 mg
价格:

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号:
品牌:
会员服务:
尊享会员价
贵宾专线
运费优惠
闪电退款
福利优惠
上门换新
友情提示
以上价格仅为参考,请联系客服询价。
免费咨询热线
4000-520-616
产品说明
Description:C3b/iC3b,Human,mAb3E7,functionalstudyantibody,lowendotoxinMonoclonalantibody3E7recognizeshumancomplementC3b/iC3bandblocksactivationofthealternativepathway(AP).Thecomplementsystemplaysimportantrolesinbothinnateandadaptiveimmuneresponseandcanproduceaninflammatoryandprotectivereactiontochallengesfrompathogensbeforeanadaptiveresponsecanoccur.Therearethreepathwaysofcomplementactivation.TheclassicalpathwayisinitiatedbyImmunecomplexes;thelectinpathwaybysurfaceboundmannanbindinglectin;andtheAPbyallthesurfacesthatarenotspecificallyprotectedagainstit.EachgeneratesaC3convertase,aserineproteasethatcleavesthecentralcomplementproteinC3,andgeneratesthemajorcleavagefragmentC3b.TheC3andC5convertasesareenzymaticcomplexesthatinitiateandamplifytheactivityofthecomplementpathwaysandultimatelygeneratethecytolyticMAC.UponactivationofC3twofragmentsaregenerated.ThesmalleranaphylatoxinC3aandthelargershortlivedC3b.Thelatterishighlyreactiveandcanbindtocomplement-activatingparticlesorimmune-complexes.Unliketheclassicalpathway,theAPisinstateofcontinuousactivation.TheAPplaysanimportantroleintissuesdamageandinflammationassociatedwithcertainautoimmunediseasesandwithischemia-reperfusioninjury.IncreasingevidencesuggestsblockingactivationofAPcanpreventorreducecertaindiseasepathologiesandmaintainhostdefenseaffordedbyCPandLP.DepositionofC3boncellsurfacescanopsonizecellsfordestruction.CellboundC3bcanbedegradedtoinactiveforms,iC3bandthenC3dg.Antibody3E7showsenhancedspecificityforC3b(i)attachedtoacellsurfaceanditcanbindtoC3b(i)-opsonizedcellsinwholeblood.TheantibodyblocksAPbasedonitscapacitytopreventC3bdepositiononthesurfaceofavarietyAPactivatorsandalsoinhibitsAP-promotedlysisofrabbiterythrocytes,asusedinthestandardAP50test.Clone3E7competeswithfactorBandHforbindingtoC3b-opsonizedsubstrates.Theuseof3E7hasbeenshowntoenhancetheimmunotherapeuticactionofRituximab.TheCPisnotaffectedorenhancedbythisantibody.Specifications:CatalognumberHM2286-FSProducttypeMonoclonalantibodiesQuantity0.5mgFormulation0.5mgof0.2μmfilteredantibodysolutioninPBS(exactconcentrationisindicatedonthelabel).ApplicationFlowcytometry,Functionalstudies,ImmunofluorescenceApplicationNotesmAb3E7blocksthealternativepathwayandnottheclassicalpathway(Ref5).UseThetypicalstartingworkingdilutionis1:50.Forfunctionalstudies,invitrodilutionshavetobeoptimizedinuser’sexperimentalsetting.ImmunogenC3b(i)-SepharoseIsotypeMouseIgG1SpeciesHumanReferences1.Kennedy,Aetal;Ananti-C3b(i)mAbenhancescomplementactivation,C3b(i)depositionandkillingofCD20cellsbyrituximab.Blood2003,101:32.Kennedy,Aetal;RituximabinfusionpromotesrapidcomplementdepletionandacuteCD20lossinChronicLymphocyticLeukemia.JournalofImmunology2004,172:53.Pawluczkowycz,Aetal;Hematinpromotescomplementalternativepathway-mediateddepositionofC3activationfragmentsonhumanerythrocytes:Potentialimplicationsforthepathogenesisofanemiainmalaria.JournalofImmunology2007,178:84.Risitano,AM;Paroxysmalnocturnalhemoglobinuriaandothercomplement-mediatedhematologicaldisorders.ImmunoBIOLOGy2012,217:115.Lindorfer,Metal;Anovelapproachtopreventingthehemolysisofparoxysmalnocturnalhemoglobinuria:bothcomplement-mediatedcytolysisandC3depositionareblockedbyamonoclonalantibodyspecificforthealternativepathwayofcomplement.Blood2010,115:116.DiLillo,Detal;SelectiveandefficientinhibitionofthealternativepathwayofcomplementbyamAbthatrecognizesC3b/iC3b.MolecularImmunology2006,43:77.Paixão-Cavalvante,Detal;Ahumanizedantibodythatregulatesthealternativepathwayconvertase:Potentialfortherapyofrenaldiseaseassociatedwithnephriticfactors.JournalofImmunology2014,192:108.Beum,Petal;ComplementactivationonBlymphocytesopsonizedwithrituximaborofatumumabproducessubstantialchangesinmembranestructureprecedingcelllysis.Journalofimmunology2008,181:1StorageandstABIlityProductshouldbestoredat4°C.Underrecommendedstorageconditions,productisstableforatleastoneyear.Theexactexpirydateisindicatedonthelabel.PrecautionsForresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandfederalrulesintheuseofthisproduct.HycultBiotechisnotresponsIBLeforanypatentinfringementsthatmightresultfromtheuseorderivationofthisproduct.DiseaseInfectiousdiseases,Nephrology

荷兰HyCult Biotechnology(HBT)位于荷兰乌登,从1994开始制造检测抗体和蛋白质,主要侧重与病理学诊断有关的全套产品研发,既有纯化的重组蛋白和多肽,也有单抗和多抗,是世界一流的先天免疫领域的研究试剂制造商。

客服在线
service-logo
已有 人查看该问题
tel
全国免费服务热线
4000-520-616
微信公众号
关注我们
手机扫码,关注动态